Evaluating Ceftolozane/Tazobactam in MDR/XDR Pseudomonas Aeruginosa

(2:5)

Evaluating Ceftolozane/Tazobactam in Immunocompromised Patients with Pseudomonas Infections

(2:9)

Jason Pogue, PharmD: Ceftolozane/Tazobactam for Drug-Resistant P aeruginosa

(3:5)

Using Ceftolozane/Tazobactam to Treat Pseudomonas Aureginosa

(2:38)

Ceftolozane-tazobactam: An Alternative Therapy to Treat Pseudomonas Infections

(32)

Treating Pseudomonas: How Does Ceftolozane-Tazobactam Differ from Other Beta-Lactams?

(24)

Investigating Pseudomonas Susceptibility to Ceftolozane/tazobactam

(1:2)

ASPECT-NP: 3-Gram Dose of Ceftolozne/Tazobactam

(2:11)

Ignacio Martin-Loeches, on the Efficacy of the ASPECT-NP Trial

(5:25)

Gaps in Available Data for Ceftolozane/Tazobactam

(44)

Marin Kollef, MD: Results of the ASPECT-NP Study

(1:49)

Collecting Real-World Data on Ceftolozane/Tazobactam

(2:)

New Antimicrobials for Multidrug Resistant Organisms -- Harrison Bachmeier, PharmD

(44:38)

CACTUS Study Compares Ceftolozane-Tazobactam vs. Ceftazidime-Avibactam for MDR Pseudomonas

(6:30)

Ceftolozane tazobactam and ceftazidime avibactam | ZMD Health Science

(26)

Treating Pseudomonas Infections With Zerbaxa or Avycaz

(5:46)

Gram-Negative NIs: Cephalosporin/β-Lactamase Inhibitors

(6:12)

Exploring Cephalosporin/β-Lactamase Inhibitor Combinations for Treatment of Pseudomonas

(5:28)

Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa

(3:15)

ZERBAXA (Ceftolozane \u0026 Tazobactam)

(9:52)